Collaborative Drug Discovery
Targeting kinase enzymes has grown to dominate drug discovery over the last decade, accounting for 30% of current pharma R&D. The analogous ubiquitin cell signalling system is the next big opportunity beyond kinases representing greater therapeutic reach. Ubiquigent has the access to the necessary technology, skills and experience to deliver Collaborative Drug Discovery Programmes to support our partners to exploit this rapidly developing field.
A typical DUB drug discovery integrated programme is given below by way of example; a similar but modified approach could be applied to other ubiquitin system targets.
Ubiquigent is focused on enabling and supporting ubiquitin system drug discovery. We recently established our own chemistry capability and launched the first novel compound library specifically designed to target ubiquitin system proteins (DUBtarget™-001). This combined with our well established biology platforms, access to high quality Research Tools and our ubiquitin system knowledge allows us to deliver ubiquitin system Collaborative Drug Discovery Programmes to our partners.
Regardless of whether you’re interested in screening for a novel deubiquitylase (DUB) enzyme inhibitor, a modulator of a ubiquitin ligase (E3) or wish to investigate any other part of the ubiquitin system, we have the assays and capabilities available to support your research programmes.
Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.
The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen).
In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.
Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.
For further details on any of our services, follow the links on the left or Contact us directly to discuss your requirements.